MNOV MediciNova Inc.

+0.39  (+4%)
Previous Close 10.61
Open 11.1
Price To Book 6.32
Market Cap 473672771
Shares 43,061,161
Volume 151,630
Short Ratio
Av. Daily Volume 115,159

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b top-line data released October 28, 2017. Primary endpoint met.
Progressive multiple sclerosis (progressive MS)
Phase 2 abstract presented at EASL April 13, 2018. Noted April 2, 2018 that trial has been terminated early due meeting one of two primary endpoints (data from second endpoint of cholesterol efflux capacity not released).
NASH (nonalcoholic steatohepatitis)
Phase 2 data released March 29, 2018 - primary endpoint not met.
Methamphetamine dependence
Phase 2b/3 trial planned.
Amyotrophic lateral sclerosis (ALS)
Phase 2/3 trial initiation announced August 6, 2018.
MN-166 (ibudilast)
Degenerative cervical myelopathy (DCM)
Phase 2 initiation announced January 8, 2019.

Latest News

  1. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of MediciNova, Inc.
  2. MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
  3. MNOV: Plans in Place for Phase 3 Trial in ALS…
  4. If You Had Bought MediciNova (NASDAQ:MNOV) Stock Five Years Ago, You Could Pocket A 536% Gain Today
  5. MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of in London, United Kingdom
  6. The Daily Biotech Pulse: FDA Greenlights AbbVie's Psoriasis Drug, Novartis Earnings, Patent Notification For MediciNova
  7. MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
  8. The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives
  9. MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS
  10. MNOV: New Analysis Shows Efficacy of MN-166 in Non-Relapsing SPMS…
  11. MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China
  12. MediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS
  13. MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania
  14. MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan
  15. MediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientific Reports
  16. MNOV: Continuing to Plan for Phase 3 Studies in Progressive MS and ALS…
  17. One Thing To Remember About The MediciNova, Inc. (NASDAQ:MNOV) Share Price
  18. MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases
  19. The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study
  20. MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma